Advances in the Treatment of HER2+ Breast Cancer

Centering discussion on a patient case of early-stage HER2+ breast cancer, expert oncologists consider when it is appropriate to utilize neoadjuvant therapy.

Comprehensive insight on the neoadjuvant treatment armamentarium for early-stage HER2+ breast cancer and the appropriate selection of specific agents.

Shifting their focus to the adjuvant setting, expert panelists review the optimal selection of therapy following surgery in early-stage HER2+ breast cancer.

A focused discussion on the subcutaneous formulation of trastuzumab and pertuzumab in patients with early-stage HER2+ breast cancer.

Panelists provide a broad overview of treatment options available for patients diagnosed with HER2+ metastatic breast cancer.

Shared insight on the DESTINY-Breast03 trial, which analyzed trastuzumab deruxtecan therapy in patients with HER2+ metastatic breast cancer.

Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.

Expert oncologists share brief notes on their real-world experience managing HER2+ metastatic breast cancer with trastuzumab deruxtecan.

Centering discussion on a patient case of HER2+ breast cancer with brain metastases, experts consider optimal treatment regimens in this setting.

Focusing on the HER2CLIMB regimen, experts consider appropriate treatment options for patients with HER2+ metastatic breast cancer in the third-line setting and beyond.

A brief discussion on treatment options available for patients with HER2+ metastatic breast cancer and brain metastases who progress on the HER2CLIMB regimen.

A broad review of CNS-related clinical trial data in the setting of HER2+ breast cancer and concurrent brain metastases.

Before closing out their discussion on HER2+ breast cancer, expert oncologists share excitement for emerging treatment strategies and ongoing clinical trials.

Chau T. Dang, MD, considers the case of a patient with early-stage HER2+ BC and discusses risk assessment and factors to consider when selecting between neoadjuvant and adjuvant treatment.

An expert in breast cancer considers the role of intravenous and fixed-dose subcutaneous formulations of trastuzumab/pertuzumab as studied in the FeDeriCa and PHranceSCa clinical trials.

Emphasizing the variety of options available in the second-line setting, Chau T. Dang, MD, remarks on the case of a patient with HER2+ mBC and highlights key factors affecting therapeutic decision-making.

A key opinion leader in oncology shares expert perspectives on safety considerations when treating patients with T-DXd in the second-line setting for HER2+ mBC.